라이라 테라퓨틱스(LYRA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.25 (+0.00%), 시가총액 $0.00B, 52주 범위 $0.09 ~ $27.58.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Infl
라이라 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
라이라 테라퓨틱스의 현재 주가는 $0.25 (+0.00%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
라이라 테라퓨틱스의 시가총액은 약 $0.00B입니다.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusit